| 发明名称 | Anti-alpha-V integrin antibody for the treatment of prostate cancer | ||
| 摘要 | The invention is directed to the treatment of prostate cancer by means of antibodies. Above all, the invention relates to the administration of an anti-alpha-v integrin (receptor) antibody to patients suffering from prostate cancer, especially castration-resistant prostate cancer (CRPC), optionally accompanied by lymph node and bone tissue metastases (mCRPC). In particular, the invention relates to the therapy of said patients by means of the anti-angiogenic antibody DI17E6 and structural mutants thereof. | ||
| 申请公布号 | US9555110(B2) | 申请公布日期 | 2017.01.31 |
| 申请号 | US201213984669 | 申请日期 | 2012.02.07 |
| 申请人 | Merck Patent GmbH | 发明人 | Hoffmann Axel;Lannert Heinrich;Brischwein Klaus;Pipp Frederic Christian;Reindl Juergen;Groll Karin;Zuehlsdorf Michael;Pfaff Otmar;Raab Sabine;Dau Ulrike;Destenaves Benoit |
| 分类号 | A61K38/00;A61K39/395;C07K16/28;C07K16/30;A61K45/06;A61K39/00 | 主分类号 | A61K38/00 |
| 代理机构 | Goodwin Procter LLP | 代理人 | Goodwin Procter LLP |
| 主权项 | 1. A method of treating a patient suffering from castrate-resistant prostate cancer (CRPC), the method comprising administering to the patient an anti-alpha integrin antibody DI17E6, wherein the antibody comprises a variable and constant light chain sequence comprising the amino acid sequence of SEQ ID NO:1 and a variable and constant heavy chain sequence comprising the amino acid sequence of SEQ ID NO:2, DI17E6 in an amount of 500 mg per two weeks for 4-8 months. | ||
| 地址 | Darmstadt DE | ||